EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

STUDY OF ADVERSE EVENTS AND BREAKTHROUGH INFECTION FOLLOWING COVID-19 VACCINATION

Srivatsav S., Vasantha Kamath*, Anand R. and Sunil S.

ABSTRACT

Background: Covid-19 pandemic which started in China in 2019 created a chaos worldwide. Since COVID-19 has no known cure, vaccinations and preventive measures like COVID-19 appropriate conduct continue to be the mainstay of security. Methods: This is a retrospective observational study where in a total of 579 individuals of either gender, above 18 years of age who had received at least one dose of any of the two COVID-19 vaccines (Covishield or Covaxin) were studied. Information was gathered using a self-designed, pretested, semi-structured questionnaire using a Google Form which was shared via WhatsApp and electronic mail to participants meeting the selection criteria. Results: Around 579 participants were studied, 87% (501) participants received covishield and 13% (78) participants received covaxin. Number of participants taking 2 doses were 85% (491). Around 79.6% (461) participants experienced adverse events after 1st dose of vaccination out of which 80.2% participants experienced after covishield and 77% participants experienced after covaxin. Around 48.06% (236) participants experienced adverse events after 2nd dose of vaccination out of which 48.9% participants experienced after covishield and 40% of participants experienced after covaxin. More number of participants experienced adverse events after 1st dose than compared to the 2nd dose and this difference was statistically significant (p ≤ 0.0001). Breakthrough infection were seen in 3.59% and 4.75% participants after 1st and 2nd dose of covishield respectively and 11.53% and 5.76% participants after 1st and 2nd dose of covaxin respectively. However, they were mild and none of them had to be hospitalized.

Keywords: COVID-19, vaccination, Adverse-events, Breakthrough infection.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 March 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: MARCH ISSUE PUBLISHED

    MARCH 2024 issue has been successfully launched on MARCH 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia